Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 14.85M shares outstanding
USBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
It also Xepi, a prescription cream for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Beth J. Hoffman, Ph.D.
Director
Dr. Hoffman
Dr. Lanckriet
Heikki Lanckriet, Ph.D.
Director
Employees
92
Country
US
Sector
Healthcare
Website
biofrontera.us.com
Loading congressional disclosures…
based on 14.85M shares outstanding
US30d Avg
546.14K
60d Avg
662.07K
90d Avg
550.95K
